NASDAQ:ACAD ACADIA Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $14.22 +0.22 (+1.57%) (As of 06/29/2022 12:00 AM ET) Add Compare Share Today's Range$13.89▼$14.3750-Day Range$13.01▼$21.3452-Week Range$12.24▼$28.06Volume1.84 million shsAverage Volume2.06 million shsMarket Capitalization$2.30 billionP/E RatioN/ADividend YieldN/APrice Target$24.63 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Stock Forecast (MarketRank)Overall MarketRank™2.80 out of 5 starsMedical Sector41st out of 1,432 stocksPharmaceutical Preparations Industry13th out of 685 stocksAnalyst Opinion: 4.2Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 - 4.2 Analyst's Opinion Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 9 buy ratings, 8 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.63, ACADIA Pharmaceuticals has a forecasted upside of 73.2% from its current price of $14.22.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Community Rank Outperform VotesACADIA Pharmaceuticals has received 824 “outperform” votes. (Add your “outperform” vote.)Underperform VotesACADIA Pharmaceuticals has received 258 “underperform” votes. (Add your “underperform” vote.)Community SentimentACADIA Pharmaceuticals has received 76.16% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote “Outperform” if you believe ACAD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $217,476.00 in company stock.Percentage Held by Insiders28.50% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.74% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow in the coming year, from ($1.41) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is -10.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is -10.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 4.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ACADIA Pharmaceuticals (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.Read More ACAD Stock News HeadlinesJune 29, 2022 | seekingalpha.comFDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run YetJune 25, 2022 | americanbankingnews.comFY2023 EPS Estimates for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Lifted by Cantor FitzgeraldJune 25, 2022 | americanbankingnews.comAnalysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $26.16June 23, 2022 | americanbankingnews.comOppenheimer Equities Analysts Cut Earnings Estimates for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)June 23, 2022 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Lowered to $19.00 at CitigroupJune 23, 2022 | americanbankingnews.comJefferies Financial Group Lowers ACADIA Pharmaceuticals (NASDAQ:ACAD) to UnderperformJune 23, 2022 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Cut to $26.00June 23, 2022 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Cut to $19.00 by Analysts at OppenheimerJune 22, 2022 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Cut to $20.00 by Analysts at HC WainwrightJune 22, 2022 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Cut to $26.00 by Analysts at Royal Bank of CanadaJune 22, 2022 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Downgraded by JPMorgan Chase & Co. to "Neutral"June 22, 2022 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 52-Week Low on Analyst DowngradeJune 21, 2022 | markets.businessinsider.comNasdaq Rises 2.5%; ACADIA Pharmaceuticals Shares PlummetSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACAD CUSIPN/A CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees514Year FoundedN/ACompany Calendar Last Earnings5/04/2022Today6/29/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$24.63 High Stock Price Forecast$35.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+73.2%Consensus RatingHold Rating Score (0-4)2.44444444444444 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)($1.330010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-167.87 million Net Margins-43.50% Pretax Margin-43.33% Return on Equity-40.52% Return on Assets-31.01% Debt Debt-to-Equity RatioN/A Current Ratio4.53 Quick Ratio4.47 Sales & Book Value Annual Sales$484.14 million Price / Sales4.75 Cash FlowN/A Price / Cash FlowN/A Book Value$3.36 per share Price / Book4.23Miscellaneous Outstanding Shares161,785,000Free Float115,676,000Market Cap$2.30 billion OptionableOptionable Beta0.68 ACADIA Pharmaceuticals Frequently Asked Questions Should I buy or sell ACADIA Pharmaceuticals stock right now? 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ACADIA Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares. View analyst ratings for ACADIA Pharmaceuticals or view top-rated stocks. What is ACADIA Pharmaceuticals' stock price forecast for 2022? 18 brokers have issued 12 month price objectives for ACADIA Pharmaceuticals' shares. Their ACAD stock forecasts range from $10.00 to $35.00. On average, they predict ACADIA Pharmaceuticals' stock price to reach $24.63 in the next year. This suggests a possible upside of 73.2% from the stock's current price. View analysts' price targets for ACADIA Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has ACADIA Pharmaceuticals' stock performed in 2022? ACADIA Pharmaceuticals' stock was trading at $23.34 at the beginning of the year. Since then, ACAD shares have decreased by 39.1% and is now trading at $14.22. View the best growth stocks for 2022 here. When is ACADIA Pharmaceuticals' next earnings date? ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for ACADIA Pharmaceuticals. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings results on Wednesday, May, 4th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.21. The biopharmaceutical company earned $115.47 million during the quarter, compared to analysts' expectations of $122.22 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 40.52% and a negative net margin of 43.50%. ACADIA Pharmaceuticals's quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.42) earnings per share. View ACADIA Pharmaceuticals' earnings history. What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings? ACADIA Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $510.00 million-$560.00 million, compared to the consensus revenue estimate of $540.68 million. Who are ACADIA Pharmaceuticals' key executives? ACADIA Pharmaceuticals' management team includes the following people: Mr. Stephen R. Davis J.D., CEO & Director (Age 61, Pay $1.03M) (LinkedIn Profile)Dr. Srdjan R. Stankovic M.D., M.S.P.H., Pres (Age 65, Pay $933.1k) (LinkedIn Profile)Mr. Mark C. Schneyer, Exec. VP & CFO (Age 48, Pay $555.49k)Mr. Brendan P. Teehan, Exec. VP, COO & Head of Commercial (Age 53, Pay $486.47k) (LinkedIn Profile)Mr. Austin D. Kim, Exec. VP, Gen. Counsel & Sec. (Age 58, Pay $559.24k) (LinkedIn Profile)Mr. James K. Kihara, VP, Chief Accounting Officer & Corp. Controller (Age 41) (LinkedIn Profile)Mr. Bob Mischler, Sr. VP of Strategy & Technology OperationsMr. Mark C. Johnson, VP of Investor RelationsMs. Julie Fisher, Sr. VP of Marketing & Commercial StrategyMs. Holly Valdiviez, Sr. VP & Head of Sales What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO? 8 employees have rated ACADIA Pharmaceuticals CEO Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among ACADIA Pharmaceuticals' employees. Who are some of ACADIA Pharmaceuticals' key competitors? Some companies that are related to ACADIA Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), Organon & Co. (OGN), Legend Biotech (LEGN), Grifols (GRFS), Maravai LifeSciences (MRVI), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Intra-Cellular Therapies (ITCI), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Hypera (HYPMY), Ultragenyx Pharmaceutical (RARE) and Cytokinetics (CYTK). View all of ACAD's competitors. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL). What is ACADIA Pharmaceuticals' stock symbol? ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD." How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ACADIA Pharmaceuticals' stock price today? One share of ACAD stock can currently be purchased for approximately $14.22. How much money does ACADIA Pharmaceuticals make? ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $2.30 billion and generates $484.14 million in revenue each year. The biopharmaceutical company earns $-167.87 million in net income (profit) each year or ($1.330010) on an earnings per share basis. How many employees does ACADIA Pharmaceuticals have? ACADIA Pharmaceuticals employs 514 workers across the globe. How can I contact ACADIA Pharmaceuticals? ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at [email protected], or via fax at 858-558-2872. This page (NASDAQ:ACAD) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
